NFE2L2 and Duchenne muscular dystrophy: Pharmacological Nrf2 activators have the potential to therapeutically exploit key targets involved in the pathogenic regulation of diseases such as DMD, which include Ca2+ dysregulation, mitochondrial dysfunction, compromised antioxidant responsivity, inflammation and impaired satellite cell-mediated regenerative activity.